|
| Press Releases |
|
 |
|
| Monday, March 14, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, February 17, 2022 |
|
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, February 16, 2022 |
|
|
中国抗体用于哮喘的第一类治疗产品SM17新药研究申请获FDA受理 |
| 中国抗体制药有限公司（“中国抗体”或“公司”，连同其附属公司，统称“集团”；股份代号：3681.HK），专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司，欣然宣布于二零二二年二月十一日（美国东部当地时间），公司已就用于哮喘的第一类（First-in-Class）治疗产品 SM17 more info >> |
|
|
中國抗體用於哮喘的第一類治療產品SM17新藥研究申請獲FDA受理 |
| 中國抗體製藥有限公司（「中國抗體」或「公司」，連同其附屬公司，統稱「集團」；股份代號：3681.HK），專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司，欣然宣佈於二零二二年二月十一日（美國東部當地時間） more info >> |
|
| Monday, February 7, 2022 |
|
|
中国抗体公布SN1011新药研究申请获中国国家药品监督管理局药品审评中心受理 |
| 中国抗体制药有限公司（“中国抗体”或“公司”，连同其附属公司，统称“集团”；股份代号：3681.HK），专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司，欣然宣布于二零二二年一月二十一日，一项SN1011的新药研究申请 more info >> |
|
|
中國抗體公佈SN1011新藥研究申請獲中國國家藥品監督管理局藥品審評中心受理 |
| 中國抗體製藥有限公司（「中國抗體」或「公司」，連同其附屬公司，統稱「集團」；股份代號：3681.HK），專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司，欣然宣佈於二零二二年一月二十一日，一項SN1011的新藥研究申請 more info >> |
|
|
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022, more info >> |
|
| Tuesday, January 11, 2022 |
|
|
中国抗体荣获“第六届金港股”评选中“最佳中小市值公司”、“最佳CEO”奖项及“2021新浪财经金麒麟最佳港美股上市公司”评选中“最具成长潜力上市公司”奖项 |
| 中国抗体制药有限公司（“中国抗体”或“公司”，连同其附属公司，统称“集团”；股份代号：3681.HK），专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司 more info >> |
|
|
中國抗體榮獲「第六屆金港股」評選中「最佳中小市值公司」、「最佳CEO」獎項及「2021新浪財經金麒麟最佳港美股上市公司」評選中「最具成長潛力上市公司」獎項 |
| 中國抗體製藥有限公司（「中國抗體」或「公司」，連同其附屬公司，統稱「集團」；股份代號：3681.HK），專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司 more info >> |
|
|
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
美國波浪機器公司宣布專利成功審查
Nov 28, 2023 23:15 HKT/SGT
|
|
|
美国波浪机器公司宣布专利成功审查
Nov 28, 2023 23:15 HKT/SGT
|
|
|
American Wave Machines, Inc. Announces Successful Review of Patents
Nov 28, 2023 23:15 HKT/SGT
|
|
|
Cultural and creative event Chill 11 debuts
Nov 28, 2023 21:00: JST
|
|
|
eDriving Launches New EcoReport Sustainability Reporting Solution for Fleets
Nov 28, 2023 21:00 HKT/SGT
|
|
|
Cultural and creative event Chill 11 debuts
Nov 28, 2023 20:00 HKT/SGT
|
|
|
OpenADR Alliance Launches New Communications Standard to Help Utilities Manage Growth in Renewable Energy Sources and EV Charging
Nov 28, 2023 18:00 HKT/SGT
|
|
|
三菱造船、液化CO2船舶輸送の実証試験船の命名引渡式を下関で実施
Nov 28, 2023 17:00: JST
|
|
|
深入布局外渠发展 国美类加盟模式释放积极效应
Nov 28, 2023 16:53 HKT/SGT
|
|
|
深入佈局外渠發展 國美類加盟模式釋放積極效應
Nov 28, 2023 16:52 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Holds Christening and Handover Ceremony in Shimonoseki for Demonstration Test Ship for Liquefied CO2 Transport
Nov 28, 2023 17:47 JST
|
|
|
Hitachi awarded Sustainable Markets Initiative 2023 Terra Carta Seal
Nov 28, 2023 17:43 JST
|
|
|
MHI Succeeded Combustion Test of Ammonia Single-Fuel Burners
Nov 28, 2023 16:40 JST
|
|
|
正利控股 (3728.HK) 2023年中期业绩盈利翻倍 展现强劲增长实力
Nov 28, 2023 15:22 HKT/SGT
|
|
|
正利控股 (3728.HK) 2023年中期業績盈利翻倍 展現強勁增長實力
Nov 28, 2023 15:21 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
